NL-201 in Patients With Relapsed or Refractory Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to understand the safety of NL-201 when given
intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to
identify a recommended dose and schedule for further testing.